UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 269

Sortiert nach

Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients

International journal of hematology, 2022-04, Vol.115 (4), p.489-498

2022

Volltextzugriff (PDF)

Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis

International journal of hematology, 2019-10, Vol.110 (4), p.419-430

2019

Volltextzugriff (PDF)

A microchip flow‐chamber assay screens congenital primary hemostasis disorders

Pediatrics international, 2021-02, Vol.63 (2), p.160-167

2021

Volltextzugriff (PDF)

Spotlight on emicizumab in the management of hemophilia A: patient selection and special considerations

Journal of blood medicine, 2019-07, Vol.10, p.171-181

2019

Volltextzugriff (PDF)

Evaluation of clinical severity in patients with type 2N von Willebrand disease using microchip-based flow-chamber system

International journal of hematology, 2020-03, Vol.111 (3), p.369-377

2020

Volltextzugriff (PDF)

Comprehensive blood coagulation potential in patients with acquired hemophilia A: retrospective analyses of plasma samples obtained from nationwide centers across Japan

International journal of hematology, 2022-02, Vol.115 (2), p.163-172

2022

Volltextzugriff (PDF)

Identification Of The Thrombin-Binding Site On Factor VIII Regulating Arg372 Cleavage In The Factor VIII Heavy Chain

Blood, 2013-11, Vol.122 (21), p.3570-3570

2013

Volltextzugriff (PDF)

The seroprevalence of neutralizing antibodies against the adeno-associated virus capsids in Japanese hemophiliacs

Molecular therapy. Methods & clinical development, 2022-12, Vol.27, p.404-414

2022

Volltextzugriff (PDF)

Correlations between global clotting function tests, duration of operation, and postoperative chest tube drainage in pediatric cardiac surgery

Pediatric anesthesia, 2011-08, Vol.21 (8), p.865-871

2011

Volltextzugriff (PDF)

Reduced plasma factor X is associated with a lack of response to recombinant activated factor VII in patients with hemophilia A and inhibitor, but does not impair emicizumab-driven hemostasis in vitro

Thrombosis research, 2024-05, Vol.237, p.37-45

2024

Volltextzugriff (PDF)

Emicizumab-mediated hemostatic function assessed by thrombin generation assay in an in vitro model of factor VIII-depleted thrombophilia plasma

International journal of hematology, 2024-02, Vol.119 (2), p.109-118

2024

Volltextzugriff (PDF)

A Novel Hemostatic Monitoring System Convertible to FVIII Activity Based on Non-Activated ROTEM (NATEM) for Hemophilia a Patients during Emicizumab Prophylaxis

Blood, 2018-11, Vol.132 (Supplement 1), p.3782-3782

2018

Volltextzugriff (PDF)

A Novel Mechanism of Factor VIIa/Tissue Factor (TF)-Catalyzed Activation and Inactivation of B-Domain-Deleted Factor VIII in the Early Initiation Phases of Coagulation

Blood, 2018-11, Vol.132 (Supplement 1), p.1162-1162

2018

Volltextzugriff (PDF)

Emicizumab‐mediated haemostatic function in patients with haemophilia A is down‐regulated by activated protein C through inactivation of activated factor V

British journal of haematology, 2018-10, Vol.183 (2), p.257-266

2018

Volltextzugriff (PDF)

Decrease in in vivo coagulant potential of emicizumab in a patient with hemophilia A and inhibitor complicated with infectious mononucleosis

Blood coagulation & fibrinolysis, 2023-03, Vol.34 (2), p.122

2023

Volltextzugriff (PDF)

Increasing of Ternary Complex Formation By Predominant Accumulation of Factor (F)X Accompanied By Increase of Fixa Contributes to Enhancement of Clotting Function By Apcc in Combination with Emicizumab

Blood, 2017-12, Vol.130, p.3658-3658

2017

Volltextzugriff (PDF)

Ex Vivo Prediction of Comprehensive Coagulation Potential Using Simulated Blood Concentrations of Emicizumab in Patients with Acquired Hemophilia A

Thrombosis and haemostasis, 2021-10, Vol.121 (10), p.1289

2021

Volltextzugriff (PDF)

Hemostatic Treatment Using Factor VIII Concentrates for Neutralizing High-Responding Inhibitors Prior to CVAD Insertion for Immune-Tolerance Induction Therapy

Clinical and applied thrombosis/hemostasis, 2012-01, Vol.18 (1), p.66-71

2012

Volltextzugriff (PDF)

Force-sensing treadmill gait analysis system can detect gait abnormalities in haemophilia patients without arthropathy

Haemophilia : the official journal of the World Federation of Hemophilia, 2024-05, Vol.30 (3), p.780-790

2024

Volltextzugriff (PDF)

Coagulant potentials of emicizumab in the plasmas from infant and toddler patients with hemophilia A

Pediatric blood & cancer, 2023-10, Vol.70 (10), p.e30590-n/a

2023

Volltextzugriff (PDF)

A New Classification of Mild/Moderate Hemophilia Α Based on a Multi-Dimensional FVIII(a) Functions Evaluated By a Plasma-Based Factor Xa Generation

Blood, 2016-12, Vol.128 (22), p.1392-1392

2016

Volltextzugriff (PDF)

Emicizumab, the bispecific antibody to factors IX/IXa and X/Xa, potentiates coagulation function in factor XI‐deficient plasma in vitro

Journal of thrombosis and haemostasis, 2019-01, Vol.17 (1), p.126-137

2019

Volltextzugriff (PDF)

Risk factors for post-extraction bleeding in patients with haemophilia: a retrospective cohort study

British journal of oral & maxillofacial surgery, 2021-04, Vol.59 (3), p.341-346

2021

Volltextzugriff (PDF)

Longitudinal dynamic changes in factor VIII inhibitor titers in patients with hemophilia A and inhibitors receiving emicizumab prophylaxis

International journal of hematology, 2023-12, Vol.118 (6), p.690-698

2023

Volltextzugriff (PDF)

Factor (F)VIII/VIIa enhances global haemostatic function in the co‐presence of bypassing agents and FVIII among patients with haemophilia A with inhibitor

British journal of haematology, 2018-05, Vol.181 (4), p.528-536

2018

Volltextzugriff (PDF)

1 – 25 von 269

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(187)
Mit Volltextzugriff
(251)

Publikationsform

Sprache

Englisch
(252)
Japanisch
(60)

Erscheinungsjahr

n.n

Thema

Science & Technology
(119)
Life Sciences & Biomedicine
(91)
Humans
(61)
Male
(43)
Cardiovascular System & Cardiology
(32)
Biological And Medical Sciences
(28)
Female
(28)
Animals
(27)
Technology
(27)
Hematology
(26)
Medical Sciences
(25)
Cardiac & Cardiovascular Systems
(23)
Computer Science
(21)
Surgery
(21)
Middle Aged
(19)
Computer Science, Artificial Intelligence
(18)
Computer Science, Interdisciplinary Applications
(18)
Computer Science, Theory & Methods
(18)
Adult
(16)
Hemophilia
(16)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients

Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis

A microchip flow‐chamber assay screens congenital primary hemostasis disorders

Spotlight on emicizumab in the management of hemophilia A: patient selection and special considerations

Evaluation of clinical severity in patients with type 2N von Willebrand disease using microchip-based flow-chamber system

Comprehensive blood coagulation potential in patients with acquired hemophilia A: retrospective analyses of plasma samples obtained from nationwide centers across Japan

Identification Of The Thrombin-Binding Site On Factor VIII Regulating Arg372 Cleavage In The Factor VIII Heavy Chain

The seroprevalence of neutralizing antibodies against the adeno-associated virus capsids in Japanese hemophiliacs

Correlations between global clotting function tests, duration of operation, and postoperative chest tube drainage in pediatric cardiac surgery

Reduced plasma factor X is associated with a lack of response to recombinant activated factor VII in patients with hemophilia A and inhibitor, but does not impair emicizumab-driven hemostasis in vitro

Emicizumab-mediated hemostatic function assessed by thrombin generation assay in an in vitro model of factor VIII-depleted thrombophilia plasma

A Novel Hemostatic Monitoring System Convertible to FVIII Activity Based on Non-Activated ROTEM (NATEM) for Hemophilia a Patients during Emicizumab Prophylaxis

A Novel Mechanism of Factor VIIa/Tissue Factor (TF)-Catalyzed Activation and Inactivation of B-Domain-Deleted Factor VIII in the Early Initiation Phases of Coagulation

Emicizumab‐mediated haemostatic function in patients with haemophilia A is down‐regulated by activated protein C through inactivation of activated factor V

Decrease in in vivo coagulant potential of emicizumab in a patient with hemophilia A and inhibitor complicated with infectious mononucleosis

Increasing of Ternary Complex Formation By Predominant Accumulation of Factor (F)X Accompanied By Increase of Fixa Contributes to Enhancement of Clotting Function By Apcc in Combination with Emicizumab

Ex Vivo Prediction of Comprehensive Coagulation Potential Using Simulated Blood Concentrations of Emicizumab in Patients with Acquired Hemophilia A

Hemostatic Treatment Using Factor VIII Concentrates for Neutralizing High-Responding Inhibitors Prior to CVAD Insertion for Immune-Tolerance Induction Therapy

Force-sensing treadmill gait analysis system can detect gait abnormalities in haemophilia patients without arthropathy

Coagulant potentials of emicizumab in the plasmas from infant and toddler patients with hemophilia A

A New Classification of Mild/Moderate Hemophilia Α Based on a Multi-Dimensional FVIII(a) Functions Evaluated By a Plasma-Based Factor Xa Generation

Emicizumab, the bispecific antibody to factors IX/IXa and X/Xa, potentiates coagulation function in factor XI‐deficient plasma in vitro

Risk factors for post-extraction bleeding in patients with haemophilia: a retrospective cohort study

Longitudinal dynamic changes in factor VIII inhibitor titers in patients with hemophilia A and inhibitors receiving emicizumab prophylaxis

Factor (F)VIII/VIIa enhances global haemostatic function in the co‐presence of bypassing agents and FVIII among patients with haemophilia A with inhibitor

Suchergebnisse filtern